(Q41021696)

25 September 2017

1 reference

title

Pharmacoeconomic studies. Pitfalls and problems (English)

1 reference

25 September 2017

De Graeve D

1

1 reference

PubMed ID

8690559

25 September 2017

Nonneman W

series ordinal

2

1 reference

PubMed ID

8690559

25 September 2017

language of work or name

1 reference

1 January 1996

1 reference

International Journal of Technology Assessment in Health Care

25 September 2017

1 reference

25 September 2017

12

1 reference

25 September 2017

1

1 reference

25 September 2017

22-30

1 reference

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

25 September 2017

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Economic evaluation of pharmaceuticals: a European perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Persons vs years: two ways of eliciting implicit weights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Social evaluation of health care versus personal evaluation of health states. Evidence on the validity of four health-state scaling instruments using Norwegian and Australian surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Toward quality assurance in QALY calculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Discounting in cost-effectiveness analysis of healthcare programmes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Exposure of the wound--a safe economy in the NHS

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Guidelines for the clinical and economic evaluation of health care technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

Economic analysis in randomized control trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

7 January 2021

Measuring utility values for QALYs: two methodological issues

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

7 January 2021

https://api.crossref.org/works/10.1017%2FS0266462300009351

1 reference

7 January 2021

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

7 January 2021

Economic evaluation of pharmaceuticals: science or marketing?

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

7 January 2021

The Reliability of Cost-Utility Estimates in Cost-Per-QALY League Tables

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

7 January 2021

Principles of cost-effective resource allocation in health care organizations

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

7 January 2021

Economic evaluation of healthcare: a half-way technology

1 reference

https://api.crossref.org/works/10.1017%2FS0266462300009351

7 January 2021

10.1017/S0266462300009351

Identifiers

DOI

1 reference

25 September 2017

1 reference

PubMed ID

8690559